Edgewise Therapeutics, Inc. (EWTX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update from Edgewise Therapeutics, Inc. confirms completion of a Phase 1 study called “A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function.” The study aims to see how the drug moves through the body in people with kidney problems versus healthy volunteers, and to check basic safety, which is key for later stage trials and dosing decisions.
The study tests EDG-7500, an oral drug given as a single dose. The goal is to see if people with mild, moderate, or severe kidney impairment handle the medicine differently, and to confirm that the dose is safe across these groups.
This is an interventional trial where all participants receive EDG-7500, but in different kidney function groups run in parallel. There is no placebo or blinding, and the main goal is basic science, focused on drug levels in the blood and safety rather than direct clinical benefit.
The study was first submitted on June 9, 2025, which signals when the trial entered the formal registry. The most recent update on March 10, 2026, shows that the study has been completed and that the sponsor has refreshed key information, an important step before any formal data release.
For investors in Edgewise Therapeutics (EWTX), a completed renal impairment study is a de-risking milestone, because clean data can support broader use and smoother regulatory reviews. In a biotech market where safety and dosing in special populations often drive valuation swings, this update may improve sentiment versus peers without such data, though the stock impact will depend on the actual results once disclosed.
The study is now completed and recently updated, and further details will be available on the ClinicalTrials portal as more information is posted.
To learn more about EWTX’s potential, visit the Edgewise Therapeutics, Inc. drug pipeline page.